Nina Riggins, MD, PhD

Although headache and COVID-19 have been linked together in the literature, more studies are needed to better understand the pathophysiology of these headaches and to determine the best treatment options.

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.

The assistant professor and neurologist at the University of California San Francisco discussed how the presence of cranial autonomic symptoms (CAS) can be a predictor of the effect of Botox on chronic migraine.

In this podcast, Dr Heidi Moawad interviews a neurologist currently researching new, available treatments in headache medicine.